

1 **Article Summary Line:** NCDs and lower income are significantly associated with higher
2 chances of infection and hospitalization due to COVID-19

3 **Running Title:** Chronic disease and COVID-19 hospitalization

4 **Keywords:** COVID-19; Noncommunicable Diseases; Comorbidities; Survey

5 **Title:** COVID-19 infection and hospitalization according to the burden of chronic
6 noncommunicable diseases in Brazil

7 **Fabiana R. Ferraz, Wolney L. Conde, Isabela Venancio, Larrisa Lopes and Catarina M.**
8 **Azeredo.**

9 **Affiliations:**

10 Universidade de São Paulo, São Paulo, São Paulo, Brazil (F. Ferraz, W. Conde, I. Venancio, L.
11 Lopes)

12 Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil (C. Azeredo)

13 **Abstract**

14 Chronic diseases, worse socioeconomic conditions and old age can increase infection and
15 hospitalization rate due to Coronavirus disease (COVID-19). We assessed the association between
16 the burden of NCDs and the occurrence of infections and hospitalizations of COVID-19 in Brazil
17 in a large COVID-19 national survey data. We analyzed only data collected between July and
18 November 2020 ($n = 1,071,782$). The frequencies of positive COVID-19 diagnosis and NCD
19 burden were estimated according to age, sex, socioeconomic strata and skin color categories. We
20 estimated hazard ratios and 95% confidence intervals using Cox regression models. There is a non-
21 linear dose-response inverse association between *per capita* income and the rates of infection and

22 hospitalization due to COVID-19. The presence of NCDs was associated with a higher incidence
23 of COVID-19 infection ($HR_{\text{NCD}} = 1.34$; 95% CI: 1.26; 1.43; $HR_{2 \text{ or more NCD}} = 1.54$ 95% CI: 1.39; 1.71)
24 and incidence of hospitalization ($HR_{\text{NCD}} = 3.08$ 95% CI: 2.26; 4.19; $HR_{2 \text{ or more NCD}} = 6.81$ 95% CI: 4.88;
25 9.49). The difference between the risks of infection or hospitalization of COVID-19 attributable to
26 the burden of NCDs is non-linearly associated with the income.

27 **Text**

28 Worldwide, over 93 million cases and over 2 million deaths have been reported since the
29 start of the Coronavirus disease (COVID-19) pandemic by the World Health Organization
30 (WHO). Brazil has reported the highest number of new cases, as of 16 March 2021 (1).

31 According to the WHO, 15% of COVID-19 cases are likely to develop into
32 hospitalizations and 5% require treatment in intensive care units (ICU) (2). Factors such as
33 comorbidities, the presence of chronic diseases, worse socioeconomic conditions and old age can
34 increase the risk of hospitalization (3). According to data from the *Pesquisa Nacional de Saúde*
35 (National Health Survey) (PNS 2019), approximately 52% of Brazilian adults have at least one
36 chronic non-communicable disease (NCD). Respiratory and cardiac diseases, diabetes and
37 hypertension are the comorbidities leading towards the worst prognosis for COVID-19 (4,5).

38 In Brazil, considering the prevalence of NCDs, nationwide estimates for adults at risk of
39 severe COVID-19 range from 34.0% (53 million) to 54.5% (86 million) (6). To date we have no
40 evidence that the presence of comorbidities increases the risk of infection or if there is a gradient
41 between the number of comorbidities and the risk of hospitalizations due to COVID-19 (7).
42 Therefore, the aim of this study was to analyze the association between the burden of NCDs and
43 the occurrence of infections and hospitalizations of COVID-19.

45 **METHODS**

46 Data

47 We used data from PNAD COVID-19 (Portuguese acronym for National Household
48 Sample Survey COVID-19), conducted by the Instituto Brasileiro de Geografia e Estatística
49 (IBGE) and the Brazilian Ministry of Health. PNAD COVID-19 survey followed,
50 through monthly telephone calls, approximately 193,000 households between May and
51 November 2020. The sample was selected from an elaborated registry of probabilistic matching
52 between addresses of households contained in the Brazilian National Household Sample Survey
53 (PNAD 2019) and addresses of six databases with telephone information. The procedures,
54 databases used, questionnaires and sample plan of the research are described in technical
55 documents from IBGE (8). For the present study, we analyzed only data from individuals
56 between 20 and 59 years of age, collected between July and November 2020 (n=2.650.459).

57 PNAD COVID-19 collected information about exams, results of COVID-19, income and
58 sociodemographic characteristics of residents. It was also asked about previous diagnosis of
59 diabetes mellitus, high blood pressure, chronic respiratory diseases (asthma, bronchitis,
60 emphysema and others), heart diseases (infarction, angina, heart failure, arrhythmia), depression
61 and cancer. Three questions related to the tested specimen were also used to diagnose COVID-19
62 infection, without discriminating the test performed (molecular biology, antigen or antibody).
63 The oronasal swab test uses the RT-PCR technique to identify viral RNA, usually up to the 8th
64 day of infection (9,10). In the venous blood test it is possible to detect antigen (current infection)
65 or antibody (current or past infection), and it is usually applied from the 8th day after the
66 beginning of the symptoms . The capillary blood test, also available for diagnosis, allows
67 verification of results after 15 minutes of the exam (11). We used three diagnostic outcomes:

68 positive diagnosis in oronasal swab, positive diagnosis in venous blood, and positive diagnosis in
69 capillary blood.

70 Sociodemographic information was also analyzed, such as sex (male and female), age (in
71 years), skin color (“white”/“yellow” and “black”/“brown”/“indigenous”), information on per
72 capita household income (PCI), which was calculated by the monthly average of individual
73 incomes divided by the total number of individuals in the household and then divided into fifths
74 of the distribution; schooling, complete or not, which was grouped into the following levels: no
75 schooling, elementary school, high school, higher education and post graduation; geographic
76 region and area of residence (urban or rural). Predicted values adjusted for NCD, age, sex,
77 education, income and skin color were created for two probabilistic outcomes, diagnosis and
78 hospitalization by COVID-19.

79 Statistical Analysis

80 For the present analysis, we carried out the following preparation: a) selection of
81 individuals between 20 and 59 years old; b) we consider any positive result reported in any of the
82 3 diagnostic tests asked; c) noncommunicable Diseases (NCD) diagnoses were grouped into 0, 1,
83 2 or more diseases to represent the NCD burden; d) we selected all cases with complete response
84 for variables under analysis (n = 1,071,782).

85 The frequencies of positive COVID-19 diagnosis and NCD burden were estimated according to
86 age, geographic and socioeconomic strata and skin color categories. We calculated hazard ratios
87 (HR) and 95% confidence intervals (CI) for the association between NCD and the risk of
88 infection and hospitalization for COVID-19 using Cox regression models via maximum
89 likelihood to account for repeated measures, as each person could contribute with one or more
90 interviews to the study. Findings at $p < 0.05$ were considered statistically significant. Initially,

91 we assessed the number of chronic noncommunicable diseases in separate models without
92 including any covariates.. Secondly, we included a priori selected demographic variables to
93 assess potential confounding: sex, age, race/skin color, education, household income and
94 rural/urban residency. The adjusted prevalence of COVID-19 was predicted according to NCD
95 burden and stratified by per capita household income. We estimated p-trends for the dose-
96 response relationship between NCD and COVID infection and hospitalization.
97 Finally, predicted values from the model were used to estimate COVID-19 latent frequency
98 according to the burden of NCD as grading risk to the infection or ICU use. All analyses were
99 performed using sampling weights in Stata® 15.1.

100 **RESULTS**

101 The prevalence of COVID-19 was higher among individuals aged 30 to 50 years (58%),
102 while the prevalence of hospitalizations was higher among individuals aged 40 or over more
103 (59%). Around 60% of the people in the age group of 40 years or over had NCDs. The
104 prevalence of 2 or more NCDs among the richest was 1.3 times the prevalence among the
105 poorest, however, the prevalence of hospitalizations was 1.2 times more frequent in the poorest
106 group.

107 The COVID-19 infection rate as a function of the NCD burden was not statistically
108 associated with sex. Table 2 shows the association between NCD burden and outcomes of
109 COVID-19. The presence of NCDs was associated with a higher incidence of COVID-19
110 infection for 1 NCD (HR = 1.34; 95% CI: 1.26; 1.43) and for 2 or more (HR = 1.54 95% CI:
111 1.39; 1.71). Also, the presence of NCDs was associated with higher incidence of hospitalization
112 for 1 NCD (HR = 3.08 95% CI: 2.26; 4.19) and for two or more NCDs (HR = 6.81 95% CI: 4.88;
113 9.49).

114 The stratification of the association between NCD and COVID-19 according to family
115 income per capita is shown in Figure 1. The risk of infection by COVID-19 according to NCD
116 tends to decrease as per capita income increases. This trend was not linear, since in the richest
117 the risk of infection fluctuates slightly in a positive way. The risk of hospitalization for COVID-
118 19 among NCD patients shows an inverse trend with per capita income, although this association
119 is tenuous.

120 In Figure 1, we observed that the risk of hospitalization among patients without NCD did
121 not vary according to income strata, even after adjusting for sex, age, education, income and skin
122 color. Among patients with NCDs infected with COVID-19, the chance of hospitalization was
123 higher among the richest than the poorest.

124 **DISCUSSION**

125 Our results suggest that: a) patients with NCDs are at high risk for infection and
126 hospitalization with the Sars-CoV-2 virus. The risk of hospitalization is approximately twice the
127 risk of infection; b) there is a non-linear dose-response type association between the risks of
128 infection and hospitalization due to COVID-19 and *per capita* income; c) the difference between
129 the risks of infection or hospitalization of COVID-19 due to the burden of NCDs is non-linearly
130 associated with the *per capita* income.

131 Worldwide, approximately one in three adults suffers from multiple chronic diseases
132 (12). In Brazil, approximately 52% of the adult population has at least one chronic disease,
133 which is responsible for 72% of the causes of death in the country (6,13).

134 The COVID-19 pandemic highlights the role of NCDs as risk factors for infection,
135 hospitalization and death. Global data show that 1.7 billion people, 22% of the world population,
136 have at least one underlying condition that puts them at increased risk for COVID-19 infection

137 (14). In Brazil, from one third (53 million) to half (86 million) of adults have at least one risk
138 factor for COVID-19 (7).

139 The association between NCDs, diagnosis and hospitalization for COVID-19, observed in
140 our study, is in line with results from other countries (15–19). A meta-analysis carried out with
141 Chinese data showed that the most prevalent comorbidities among patients with COVID-19 were
142 hypertension (21%), diabetes (10%), cardiovascular disease (8%) and respiratory system disease
143 (2%). The combined OR for presenting a severe case among those with hypertension,
144 respiratory system disease and cardiovascular disease was 2.36 (95% CI: 1.46; 3.83), 2.46 (95%
145 CI: 1.76; 3.44) and 3.42 (95% CI: 1.88; 6.22) respectively (15). Analyzes based on American
146 clinical data indicate that the majority of outpatients with COVID-19 studied were African
147 American (72%), and had at least one comorbidity (94%), including hypertension (64%), chronic
148 kidney disease (39 %) and diabetes (38%). Severe obesity (OR = 2.0; 95% CI: 1.4; 3.6) and
149 having chronic kidney disease (OR = 2.0; 95% CI: 1.3; 3.3) were the strongest predictors for
150 admission to the intensive care unit (16).

151 Increasing evidence suggests that NCDs are determinants of the prognosis for infectious
152 diseases (20). The gradient between the number of NCDs and the evolution to a bad prognosis of
153 COVID-19, as found in the present study, brings up new challenges. The policy makers need to
154 take into account the management of actions that strengthen equity attention to the social and
155 biologically vulnerable population when elaborating strategies for health care (19).

156 Our results indicate that poorer individuals are more vulnerable to contagion and
157 hospitalization due to COVID-19 in Brazil. Previous population epidemiological data (H1N1 and
158 SARS) demonstrates the impact of social inequality as determinants for higher contagion and
159 severity of these diseases (21–23). Factors such as lower wages, quality of public transport,

160 unsanitary housing conditions, inefficient health care and difficulty in maintaining social
161 isolation without significant loss of income corroborate the increased vulnerability of this
162 population. (24,25). With regard to inequality in access to health and the needs to cope with the
163 pandemic of COVID-19, there is an increase in the demand for health care and intensive care
164 beds (ICU) with a range of attention to the population with dependence on public health care
165 (3,26).

166 In Brazil, 71.5% of the population exclusively uses public health services, showing a
167 direct relationship with income ranges *per capita* (27). The recommendation of WHO about the
168 adequate ratio of Intensive Care (ICU) beds is 1 to 3 beds for every 10,000 inhabitants. In Brazil,
169 the SUS (portuguese acronym for National Public Health System) has an average of 1.4 beds for
170 every 10,000 inhabitants against 4.9 in private health service (28).

171 Our findings revealed that among NCDs patients infected with COVID-19, the chance of
172 hospitalization was higher for the richest relative to the poorest. Income determinants seem to be
173 associated with less access to health and intensive treatment of the disease. In our interpretation,
174 poorer individuals, even though they are more vulnerable to the contagion of the disease, are less
175 likely to obtain access to treatment and hospitalization for COVID-19.

176 As a limitation of the study, the classic limitations of observational studies can be cited,
177 such as: self-report of information and lack of specificity and limited amount of information on
178 clinical diagnoses. Thus, our analyzes were conditioned to the volume and type of information
179 available in the database. As strengths of the study, longitudinal monitoring and the national
180 representativeness of the home-based sample can be pointed out, with a high response rate. In
181 addition, the sample size allows for consistent stratifications throughout the analysis (29).

182 These findings and methods of estimating the impact of vulnerable groups on the
183 progression of the pandemic may be useful for planning and managing prevention and treatment
184 strategies in Brazil. A better management and direction of policies that aim to obey the principle
185 of universality of rights in health care, covering the population in a state of biological and social
186 vulnerability is necessary. It is imperative to protect groups at greatest risk, such as people with
187 chronic diseases and comorbidities in scenarios of broad measures of social isolation,
188 particularly while the capacity for immunization is limited.

189 **CONCLUSION**

190 The burden of NCDs increases the risk of infection and hospitalization by COVID-19.
191 This is troublesome in a context of increasing social and health inequalities as in Brazil.
192 This situation, associated with the prospects caused by COVID-19, projects a scenario of
193 increased demand for clinical care in the coming years.

194

195 **Author Bio**

196 Researcher and member of the Laboratory of Nutritional Assessment of Populations of
197 the University of São Paulo. Currently study epidemiological and nutritional developments in
198 populations.

199 **References**

- 200 1. WHO. Weekly epidemiological update - 19 January 2021 [Internet]. 2021 Jan [cited
201 February 18, 2021]. Available in: <https://www.who.int/publications/m/item/weekly-epidemiological-update---19-january-2021>.
202

- 203 2. OMS. Oxygen sources and distribution for COVID-19 treatment centres [Internet]. 2020
204 [cited February 19, 2021]. Available in: [https://www.who.int/publications-detail-](https://www.who.int/publications-detail-redirect/oxygen-sources-and-distribution-for-covid-19-treatment-centres)
205 [redirect/oxygen-sources-and-distribution-for-covid-19-treatment-centres](https://www.who.int/publications-detail-redirect/oxygen-sources-and-distribution-for-covid-19-treatment-centres)
- 206 3. Noronha KVM de S, Guedes GR, Turra CM, Andrade MV, Botega L, Nogueira D, et al.
207 Pandemia por COVID-19 no Brasil: análise da demanda e da oferta de leitos hospitalares
208 e equipamentos de ventilação assistida segundo diferentes cenários. *Cad Saúde Pública*.
209 2020;36:e00115320.
- 210 4. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
211 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases
212 From the Chinese Center for Disease Control and Prevention. *JAMA*. 7 de abril de
213 2020;323(13):1239–42.
- 214 5. Malta DC, de Moura L. Probabilidade de morte prematura por doenças crônicas não
215 transmissíveis, Brasil e regiões, projeções para 2025. 2019;13.
- 216 6. Instituto Brasileiro de Geografia e Estatística. Pesquisa Nacional de Saúde 2019:
217 Percepção do estado de saúde, estilos de vida, doenças crônicas e saúde bucal [Internet].
218 Rio de Janeiro, RJ - Brasil; 2019 [citado 18 de fevereiro de 2021]. 113 p.
- 219 7. Rezende LFM, Thome B, Schweitzer MC, Souza-Júnior PRB de, Szwarcwald CL. Adults
220 at high-risk of severe coronavirus disease-2019 (Covid-19) in Brazil. *Rev Saúde Pública*.
221 2020;54:50–50.
- 222 8. IBGE. PNAD COVID19 – Plano amostral e ponderação. Rio de Janeiro: IBGE; 2020. 7
223 p.
- 224 9. Caliendo A, Hanson K. COVID-19: Diagnosis [Internet]. UpToDate. 2021 [citado 16 de
225 março de 2021]. Disponível em: <https://www.uptodate.com/contents/covid-19-diagnosis>

- 226 10. Ministério da Saúde. Sobre a doença [Internet]. 2020 [citado 16 de março de 2021].
227 Disponível em: <https://coronavirus.saude.gov.br/sobre-a-doenca>
- 228 11. FDA U.S. Food & Drugs. Coronavirus Testing Basics. Coronavirus Test Basics. maio de
229 2020;3.
- 230 12. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional,
231 and national age-sex-specific mortality for 282 causes of death in 195 countries and
232 territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study
233 2017. *The Lancet*. 10 de novembro de 2018;392(10159):1736–88.
- 234 13. Malta DC, Moura L de, Prado RR do, Escalante JC, Schmidt MI, Duncan BB. Chronic
235 non-communicable disease mortality in Brazil and its regions, 2000-2011. *Epidemiol E*
236 *Serviços Saúde*. dezembro de 2014;23(4):599–608.
- 237 14. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global,
238 regional, and national estimates of the population at increased risk of severe COVID-19
239 due to underlying health conditions in 2020: a modelling study. *Lancet Glob Health*. 1º de
240 agosto de 2020;8(8):e1003–17.
- 241 15. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and
242 its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.
243 *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. maio de 2020;94:91–5.
- 244 16. Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, et al. Clinical
245 Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of
246 Patients in Metropolitan Detroit. *JAMA Netw Open* [Internet]. 16 de junho de 2020
247 [citado 22 de março de 2021];3(6). Disponível em:
248 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298606/>

- 249 17. Xiong S, Liu L, Lin F, Shi J, Han L, Liu H, et al. Clinical characteristics of 116
250 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective,
251 observational study. *BMC Infect Dis* [Internet]. 22 de outubro de 2020 [citado 22 de
252 março de 2021];20. Disponível em:
253 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578439/>
- 254 18. Albashir AAD. The potential impacts of obesity on COVID-19. *Clin Med*. julho de
255 2020;20(4):e109–13.
- 256 19. Azarpazhooh MR, Morovatdar N, Avan A, Phan TG, Divani AA, Yassi N, et al. COVID-
257 19 Pandemic and Burden of Non-Communicable Diseases: An Ecological Study on Data
258 of 185 Countries. *J Stroke Cerebrovasc Dis*. setembro de 2020;29(9):105089.
- 259 20. Ogoina D, Onyemelukwe GC. The role of infections in the emergence of non-
260 communicable diseases (NCDs): Compelling needs for novel strategies in the developing
261 world. *J Infect Public Health*. 2009;2(1):14–29.
- 262 21. Tricco AC, Lillie E, Soobiah C, Perrier L, Straus SE. Impact of H1N1 on Socially
263 Disadvantaged Populations: Systematic Review. *PLoS ONE* [Internet]. 25 de junho de
264 2012 [citado 23 de março de 2021];7(6). Disponível em:
265 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382581/>
- 266 22. Cordoba E, Aiello AE. Social Determinants of Influenza Illness and Outbreaks in the
267 United States. *N C Med J*. outubro de 2016;77(5):341–5.
- 268 23. Bucchianeri GW. Is SARS a Poor Man’s Disease? Socioeconomic Status and Risk
269 Factors for SARS Transmission. *Forum Health Econ Policy* [Internet]. 22 de julho de
270 2010 [citado 23 de março de 2021];13(2). Disponível em:
271 <https://www.degruyter.com/document/doi/10.2202/1558-9544.1209/html>

- 272 24. Carvalho L, Nassif Pires L, de Lima Xavier L. COVID-19 e Desigualdade no Brasil.
273 2020.
- 274 25. Michigan Department of Health and Human Services (MDHHS). COVID-19 response
275 and mitigation strategies for racial and ethnic populations and marginalized communities
276 [Internet]. 2020 [citado 23 de março de 2021]. Disponível em:
277 [https://www.michigan.gov/documents/mdhhs/OEMH_COVID-](https://www.michigan.gov/documents/mdhhs/OEMH_COVID-19_Response_Mitigation_Strategies_Targeting_Racial_Ethnic_Populations_Marginalized_Communities_FINAL_689586_7.pdf)
278 [19_Response_Mitigation_Strategies_Targeting_Racial_Ethnic_Populations_Marginalize](https://www.michigan.gov/documents/mdhhs/OEMH_COVID-19_Response_Mitigation_Strategies_Targeting_Racial_Ethnic_Populations_Marginalized_Communities_FINAL_689586_7.pdf)
279 [d_Communities_FINAL_689586_7.pdf](https://www.michigan.gov/documents/mdhhs/OEMH_COVID-19_Response_Mitigation_Strategies_Targeting_Racial_Ethnic_Populations_Marginalized_Communities_FINAL_689586_7.pdf)
- 280 26. Daumas RP, Silva GA, Tasca R, Leite I da C, Brasil P, Greco DB, et al. O papel da
281 atenção primária na rede de atenção à saúde no Brasil: limites e possibilidades no
282 enfrentamento da COVID-19. *Cad Saúde Pública*. 2020;36:e00104120.
- 283 27. Instituto Brasileiro de Geografia e Estatística. Pesquisa Nacional de Saúde 2019:
284 Informações sobre domicílios, acesso e utilização dos serviços de saúde [Internet]. Rio de
285 Janeiro, RJ - Brasil; 2019 [cited 18 de fevereiro de 2021]. 113 p. Disponível em:
286 <https://biblioteca.ibge.gov.br/visualizacao/livros/liv101748.pdf>
- 287 28. Associação de Medicina Intensiva Brasileira. Dados atualizados sobre leitos de UTI no
288 Brasil. 2020.
- 289 29. Penna GO, Silva JAÁ, Cerbino Neto J, Temporão JG, Pinto LF. PNAD COVID-19: um
290 novo e poderoso instrumento para vigilância em saúde no Brasil. PNAD COVID-19: a
291 powerful new tool for public health surveillance in Brazil [Internet]. 2020 [citado 6 de
292 abril de 2021]; Disponível em: <https://www.arca.fiocruz.br/handle/icict/43323>
293

294 **Address for correspondence:** Fabiana Ribeiro Ferraz, Laboratório de Avaliação Nutricional de
 295 Populações, Universidade de São Paulo, Av. Dr. Arnaldo, 715 São Paulo, Brasil; email:
 296 fabianaferraznutri@gmail.com; +55(11)99704-4503

297 Table 1. Prevalence of Chronic Noncommunicable Diseases and gross probability of positive
 298 diagnosis and hospitalization for COVID-19. Brazil PNAD COVID-19, 2020.

299

300

Characteristics	Noncommunicable Diseases (%)			COVID-19 (%)	
	None	1	2 or more	Confirmed cases	Hospitalization
Brazil	79.2	16.0	4.8	3.2	6.8
Age					
20 - 30	30.9	13.7	4.7	23.8	16.1
30 - 40	29.1	19.8	12.2	30.3	24.9
40 - 50	24.0	30.4	30.4	27.3	30.1
50 - 59	16.0	36.1	52.7	18.6	28.9
Gender					
Male	49.5	41.3	34.1	44.2	46.2
Female	50.5	58.7	65.9	55.8	53.8
Geographic Region					
N	13.1	9.7	8.1	20.4	14.3
NE	30.8	28.6	26.4	31.6	26.2
SE	28.6	32.0	33.1	22.1	24.9
S	16.8	18.5	20.7	11.3	16.5
CW	10.7	11.2	11.7	14.6	18.1
Area					
Urban	76.9	78.1	78.6	87.6	82.5
Rural	23.1	21.9	21.4	12.4	17.5
Per capita household income (5^o)					

1 (poorest)	23.1	19.8	15.1	29.2	20.8
2	22.1	21.5	21.2	22.5	25.0
3	20.9	21.2	21.2	17.8	19.4
4	18.6	20.2	22.8	15.6	17.5
5 (richest)	15.3	17.3	19.7	14.9	17.3
Schooling					
No schooling	2.4	3.4	4.8	1.4	2.9
Elementary school	28.5	36.8	45.0	19.3	29.3
High school	42.6	35.1	31.4	40.9	40.3
Higher education	22.6	19.8	14.8	31.6	23.0
Post graduation	3.9	4.9	4.0	6.8	4.5
Skin color					
White/Yellow	40.7	42.5	44.0	39.4	40.3
Black/Pardo/Indigenous	59.3	57.5	56.0	60.6	59.7
Month					
July	20.0	20.3	21.0	11.9	25.4
August	20.3	19.4	18.8	16.6	21.0
September	20.2	20.1	20.0	20.7	18.5
October	19.7	20.0	20.1	23.7	14.9
November	19.8	20.2	20.1	27.1	20.2

301

302 Table 2. Cox models of risks of positive diagnosis and hospitalizations due to COVID-19 for

303 Noncommunicable Diseases (NCD). Brazil PNAD COVID-19, 2020.

304

Number of NCD	Individuals with COVID-19 N(%) / Individuals without COVID-19 N(%)	Fully-adjusted HR (95%CI)	Individuals hospitalized due to COVID-19 N(%) / Individuals not hospitalized N(%)	Fully-adjusted HR (95%CI)
None	4,163(3.38) / 119,070(96.62)	1	255(0.21) / 122,978(99.79)	1
1	1,163(4.62) / 23,997(95.38)	1.34(1.26;1.43)	84(0.33) / 25,076(99.67)	3.08(2.26;4.19)
2 or more	404(5.47) / 6,987(94.53)	1.54(1.39;1.71)	70(0.95) / 7,321(99.05)	6.81(4.88;9.49)


p-trend	-	<0.001	-	<0.001
----------------	---	--------	---	--------

305

306 Figure 1. Adjusted prevalence of COVID-19 and hospitalization for COVID-19, according
307 to the amount of NCDs and fifths of income, in Brazilian adults aged 20 to 59 years. Brazil PNAD
308 COVID-19 (2020).

309

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.03.21256532>; this version posted May 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



Data: PNAD COVID-19 [IBGE, 2020]

* Adjusted for age, place of residence, income *per capita*, schooling